Company newsForm 8-K and release
SELLAS Life Sciences Group prices 11,538,462-share offering at $13.00 per share
The company said it expects gross proceeds of $150.0 million before underwriting discounts and commissions and offering expenses.
GetSignal
On November 18, 2026, SELLAS Life Sciences Group entered into an underwriting agreement with J.P. Morgan Securities LLC and TD Securities (USA) LLC, as representatives of the underwriters, for a public offering of 11,538,462 shares of its common stock, par value $0.0001 per share. All of the shares are being sold by the company at $13.00 per share.
The underwriters also received a 30-day option to buy up to 1,730,769 additional shares of common stock on the same terms. The company said it expects net proceeds of approximately $161.8 million, including proceeds from the underwriters' full exercise of the option, after underwriting discounts and commissions and estimated offering expenses.
The offering is being made under the company's shelf registration statement on Form S-3, which was automatically effective upon filing. A final prospectus supplement supplements that registration statement.
The underwriting agreement includes customary representations, warranties, closing conditions and termination provisions. It also provides for indemnification between the company and the underwriters, including for liabilities under the Securities Act of 1933, as amended.
Key facts
- Price per share
- $13.00
- Shares offered
- 11,538,462 shares of common stock
- Underwriter option
- Up to 1,730,769 additional shares for 30 days
- Expected gross proceeds
- $150.0 million before underwriting discounts and offering expenses
- Expected net proceeds
- Approximately $161.8 million, including full exercise of the option
Sources: Form 8-K filed November 20, 2026, and the company's release on GlobeNewswire, November 17, 2026.
Written by GetSignal with AI from the company's press release. How we make news
Not investment advice.
More company news
SELLAS Life Sciences Group first, then the newest- SELLAS Life Sciences Group closes public offering for $172.5 million gross
SLS · SELLAS Life Sciences Group · Company release · Nov 20, 2026
- SELLAS says Phase 3 REGAL trial of galinpepimut-S met its primary endpoint in AML
SLS · SELLAS Life Sciences Group · Form 8-K and release · Nov 17, 2026
- Western Digital stockholders elect nine directors at annual meeting
WDC · Western Digital · Form 8-K · Nov 20, 2026
- Ares Capital subsidiary amends BNP Paribas funding facility
ARCC · Ares Capital · Form 8-K · Nov 20, 2026
